Kura Oncology Q2 EPS Lowered by Brookline Capital Markets

Kura Oncology, Inc. (NASDAQ:KURA) – Brookline Capital Markets decreased their Q2 2026 earnings estimates for shares of Kura Oncology in a research note issued to investors on Friday, May 22nd. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of ($1.02) per share for the quarter, down from their prior forecast of ($0.84). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.23) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($3.65) EPS, FY2027 earnings at ($2.54) EPS, FY2028 earnings at ($2.38) EPS, FY2029 earnings at $6.01 EPS and FY2030 earnings at $18.49 EPS.

KURA has been the subject of a number of other reports. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Tuesday, April 21st. Lake Street Capital assumed coverage on shares of Kura Oncology in a research note on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target on the stock. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Finally, UBS Group reaffirmed a “buy” rating and set a $15.00 target price (down from $16.00) on shares of Kura Oncology in a research report on Friday, March 13th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $26.38.

Kura Oncology Stock Down 7.5%

NASDAQ KURA opened at $10.41 on Wednesday. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. Kura Oncology has a 52 week low of $5.45 and a 52 week high of $12.49. The firm has a market capitalization of $924.14 million, a price-to-earnings ratio of -3.11 and a beta of 0.32. The company has a fifty day moving average of $9.09 and a two-hundred day moving average of $9.46.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC increased its holdings in shares of Kura Oncology by 5.7% during the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock valued at $89,099,000 after acquiring an additional 459,422 shares in the last quarter. Vanguard Group Inc. grew its position in Kura Oncology by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after purchasing an additional 39,105 shares during the last quarter. Armistice Capital LLC increased its stake in Kura Oncology by 5.7% during the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock valued at $51,285,000 after purchasing an additional 264,000 shares in the last quarter. State Street Corp increased its stake in Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Kura Oncology by 36.6% in the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.